Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

The following agents will be studied:

Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF; Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir, Aptivus, TPV; Indinavir, Crixivan; abacavir; raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc, Celsentri; dolutegravir; elvitegravir/cobicistat; rilpivirine, TAF, darunavir/cobicistat; doravirine; bictegravir; cabotegravir/rilpivirine long acting injectables

Inclusion criteria

• HIV-infected as documented by positive HIV antibody test and confirmed by an antigen test.
• Subject is at least 18 years of age at screening.
• Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
• Treated with a cART regimen containing at least one agent which is mentioned in Appendix 1; this agent has been taken for at least 2 weeks before the day of first PK curve evaluation.
• Subject is pregnant
• Subject is able to adhere to food intake recommendations, if applicable.

Exclusion criteria

• Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
• Inability to understand the nature and extent of the study and the procedures required.
• Presence of grade III/IV anemia (i.e. Hb <4.6 mmol/L or <7.4 g/dL).
• Using oral cabotegravir/rilpivirine.